LLY vs VRTX
LLY: Eli Lilly is a global pharmaceutical innovator leading the market in metabolic health, including diabetes and obesity treatments, alongside a diverse portfolio of oncology and immunology therapies. VRTX: Vertex is a leader in biotechnology primarily recognized for its dominance in cystic fibrosis therapy and its emerging pipeline of gene-editing treatments and non-opioid pain relief.
Side-by-side fundamentals
| Metric | LLY | VRTX | Edge |
|---|---|---|---|
| Price as of 2026-08-24 close | $1,246.93 | $547.59 | |
| Market cap as of 2026-08-24 | $1.17T | $138.8B | |
| P/E as of 2026-08-24 | 41.85 | 31.86 | VRTX lower |
| PEG as of 2026-08-24 | 1.48 | 2.28 | LLY lower |
| Net margin as of 2026-08-24 | +33.5% | +35.0% | VRTX higher |
| Gross margin as of 2026-08-24 | +83.4% | +86.0% | VRTX higher |
| Operating margin as of 2026-08-24 | +42.2% | +38.0% | LLY higher |
| ROE as of 2026-08-24 | +92.6% | +23.3% | LLY higher |
| ROA as of 2026-08-24 | +22.0% | +16.9% | LLY higher |
| Debt / equity as of 2026-08-24 | 1.62 | 0.00 | VRTX lower |
| Revenue growth (YoY) as of 2026-08-24 | +49.6% | +10.2% | LLY higher |
| Revenue CAGR (3y) SEC XBRL | +31.7% | +10.4% | LLY higher |
| Dividend yield as of 2026-08-24 | +0.8% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-24 | 0.55 | 0.48 | |
| 1-year return as of 2026-08-24 close | +75.2% | +38.6% | LLY higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.